Lifevantage Corp (LFVN) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2024 (Fiscal Q2 2025). Lifevantage Corporation is a nutrigenomics company operating a direct sales model globally, selling dietary supplements, skin care, and wellness products through a network of independent consultants. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $67.8 million | $51.6 million | $115.0 million | $103.0 million |
| Gross Profit | $54.6 million (80.5%) | $40.6 million (78.6%) | $92.3 million (80.3%) | $81.7 million (79.4%) |
| Operating Income | $3.4 million | ($1.3 million) | $6.0 million | ($0.5 million) |
| Net Income | $2.6 million | ($0.7 million) | $4.4 million | ($0.03 million) |
| Diluted EPS | $0.19 | ($0.05) | $0.34 | $0.00 |
| Cash & Equivalents | $21.6 million | $17.3 million | $21.6 million | $17.3 million |
| Working Capital | $18.2 million | $15.3 million | $18.2 million | $15.3 million |
| Debt Outstanding | $0 | $0 | $0 | $0 |
Note: All figures in millions unless otherwise noted. Percentages represent gross margin.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 31.3% year-over-year for the quarter and 11.7% year-over-year for the six-month period. This growth was primarily driven by the October 2024 launch of the MindBody GLP-1 System in the U.S. market.
- Profitability: The company returned to profitability, reporting net income of $2.6 million for the quarter compared to a net loss of $0.7 million in the prior year quarter. Operating income improved from a loss of $1.3 million to a profit of $3.4 million.
- Geographic Performance:
- Americas: Revenue surged 46.3% (quarter) and 21.2% (YTD), driven by U.S. sales growth of 48.8%.
- Asia/Pacific & Europe: Revenue declined 15.5% (quarter) and 17.6% (YTD), impacted by a 13.9% decrease in active accounts and unfavorable foreign currency fluctuations, particularly in Japan.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased as a percentage of revenue (27.5% vs. 38.9% prior year) due to reduced proxy contest expenses and the termination of a sports endorsement agreement. However, commissions and incentives increased to 48.0% of revenue (from 42.1%) due to higher qualifications in promotional programs.
Guidance, Outlook, and Risks
- Outlook: Management plans to expand the MindBody GLP-1 System internationally in the second half of fiscal 2025. They expect this expansion to drive global revenue growth through increased average order sizes and consultant retention.
- Liquidity: The company holds $21.6 million in cash and cash equivalents. It maintains a $5.0 million revolving credit facility with Bank of America (undrawn as of period end) and believes current resources are sufficient for the next 12 months.
- Capital Allocation: The company paid $1.0 million in cash dividends for the six-month period and repurchased $1.1 million of common stock. Approximately $19.3 million remains available under the share repurchase program.
- Risks: Key risks include dependence on independent consultants, foreign currency fluctuations, supply chain disruptions, and the ability to attract new customers. The company also faces risks related to regulatory compliance in various international markets.
Investor Verification Checklist
- Product Mix Sustainability: Verify the continued sales momentum of the MindBody GLP-1 System and its impact on gross margins as the product matures.
- International Headwinds: Monitor the decline in active accounts in the Asia/Pacific & Europe region and the effectiveness of strategies to reverse this trend.
- Commission Rates: Track the trend of commissions and incentives as a percentage of revenue, which rose to 48.0% in Q2, to ensure it does not erode operating margins.
- Currency Impact: Assess the ongoing impact of foreign exchange rates, particularly the Japanese Yen, on reported revenue and earnings.
- Debt Covenants: Confirm continued compliance with the financial covenants of the 2024 Credit Facility, although no debt is currently outstanding.